FDA 483 - Sohan L. Dua, M.D - September 21, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Sohan L. Dua, M.D. in Northridge, CA, a clinical investigator for the TRAVERSE study, revealed significant deficiencies in clinical trial conduct. Observations included the failure to promptly report serious adverse events, including a subject's death, to the study sponsor. Additionally, the firm failed to report unanticipated problems involving risk to human subjects to the Institutional Review Board and did not consistently obtain proper informed consent from subjects.
ID · c871bb55-63f7-4fd2-902f-448c31cc7883